Longevity & Wellness

NAD+ and Longevity: What's Actually Proven in Humans (and What's Still a Mouse Study)

NAD+ and longevity marketing has a habit of sliding from "raises NAD+ levels" (shown in people) to "slows aging" (shown in mice) as if they're the same claim. They aren't. Here's what human trials of NMN, NR, and NAD+ IV therapy have actually measured, what they haven't, and how to find out whether any of it is doing something for you specifically.

The mouse-to-human gap in NAD+ claims

NAD+ (nicotinamide adenine dinucleotide) is a coenzyme every cell needs for energy production and DNA repair, and it's genuinely true that levels decline with age. That part of the story is well established. What gets blurry is the next step: the leap from "NAD+ declines with age" to "raising it will extend your life," which is a claim built almost entirely on rodent data.

The foundational study behind most NAD+ longevity marketing is a 2016 mouse study published in Science, where researchers fed aging mice the NAD+ precursor nicotinamide riboside and found it protected muscle, neural, and melanocyte stem cells from age-related decline and extended the treated animals' life span. That's a real, well-conducted, peer-reviewed result. It is also a mouse result. Mice are not small humans, and a compound that extends rodent life span has, historically, a poor track record of doing the same in people once it reaches human trials.

This isn't a knock on the researchers, who are generally careful about the distinction themselves. It's a description of how that distinction tends to get lost by the time it reaches a supplement label or an IV clinic's Instagram post. The honest starting point for any "NAD+ and longevity" conversation is separating what's been shown in animals from what's been shown in people, and the human evidence is real, just narrower than the marketing suggests.

It's also worth being clear about why that gap is so common in longevity research generally, not just for NAD+. Mice have short lifespans, controlled genetics, and identical diets and environments, which makes it far easier to detect a life span effect in a two or three year study. Humans live decades, have wildly variable genetics and lifestyles, and can't ethically be kept in identical controlled conditions for a lifespan trial. That's not a flaw specific to NAD+ research, it's a structural limitation of studying human aging at all, and it's a big part of why so much of the field relies on shorter-term biomarker and functional measures as stand-ins for the outcome everyone actually cares about.

What's actually proven in humans

Start with the part that isn't in dispute: giving people the right NAD+ precursor, at an adequate dose, reliably raises their blood NAD+ levels. This has been replicated across multiple independent trials using different precursor molecules, and it's about as close to settled as nutrition science gets. Cleveland Clinic's own review of the evidence describes NAD+ precursor supplements as generally safe and effective at raising NAD+ levels, while noting that proof of downstream anti-aging benefit in humans is still limited. That's the accurate one-sentence summary of where the field actually stands: the biomarker moves, reliably; what that movement does for your long-term health is the part still being worked out.

The mechanism explains why researchers expected the biomarker to matter in the first place. NAD+ is a required cosubstrate for sirtuins and PARP enzymes, both directly involved in DNA repair and cellular stress response, and a widely cited 2015 review in Science described how cellular NAD+ concentrations shift with age in ways that constrain these repair pathways, and proposed that restoring NAD+ availability could be a therapeutic angle worth pursuing. It's a plausible, well-reasoned mechanism. It's still a mechanism, not a completed outcome trial in people.

What makes the biomarker finding more trustworthy than a single study is that it's been replicated across independent research groups using different NAD+ precursor molecules, different dosing schedules, and different measurement methods, and they consistently land on the same basic result: give a healthy adult an adequately dosed precursor for a month or two, and their blood NAD+ level goes up. That kind of cross-study consistency is exactly what should make you more confident in a finding, and it's a genuinely different standard than a single flashy headline result.

NMN vs NR vs NAD+ IV: what the trials used and found

"NAD+ supplementation" isn't one product either. The three routes people actually use, oral nicotinamide mononucleotide (NMN), oral nicotinamide riboside (NR), and intravenous NAD+ infusions, have different evidence bases, different regulatory status, and were tested at different doses for different outcomes. It's worth knowing what each trial actually looked like before comparing the routes side by side.

The most cited human NMN trial is a randomized, placebo-controlled study of 80 healthy adults aged 40 to 65, published in GeroScience, which tested 300, 600, and 900 mg daily doses of NMN over 60 days and found a dose-dependent rise in blood NAD+ alongside improvements in six-minute walk distance and self-reported health scores. Notably, the study's own authors flagged in their introduction that although NMN improves healthspan and lifespan in animal studies, it remains unclear whether those effects transfer to humans, which is a useful admission to see written directly into a peer-reviewed paper rather than left out of it.

NR's strongest functional-outcome data comes from a different kind of trial entirely. The NICE randomized clinical trial, published in Nature Communications, tested nicotinamide riboside with and without resveratrol against placebo in people with peripheral artery disease, and found NR meaningfully improved six-minute walk distance while resveratrol added no additional benefit. That's a clinical population with a specific vascular impairment, not a general healthy-adult longevity study, which matters when deciding how far to generalize the result.

NAD+ IV infusion has the newest and thinnest direct comparison. A 2026 pilot study in Frontiers in Aging directly compared intravenous NAD+ against intravenous NR for tolerability and short-term metabolic markers in a real-world clinic setting, finding both reasonably well tolerated, with NR infused more rapidly and with milder side effects. The authors were explicit that their metabolic outcomes were variable and that larger, longer, placebo-controlled trials are still needed before effectiveness claims can be supported.

Route	What a real human trial tested	What it found	Where the evidence is thin
NMN (oral)	80 healthy adults, aged 40 to 65, given 300, 600, or 900 mg NMN daily for 60 days in a randomized, placebo-controlled trial	Blood NAD+ rose in a dose-dependent way, with 600 mg producing the largest effect; 6-minute walk distance and self-reported health scores improved versus placebo	Single 60-day trial, one manufacturer's product, no long-term or mortality data
NR (oral)	People with peripheral artery disease given nicotinamide riboside, with and without resveratrol, versus placebo, tracking walking capacity over months	NR meaningfully improved 6-minute walk distance in this specific patient population; resveratrol added no extra benefit	Tested in a disease population with vascular impairment, not general healthy-adult longevity
NAD+ IV infusion	A 2026 pilot study directly comparing NAD+ IV against NR IV for tolerability and short-term metabolic markers in a real-world clinic setting	Both were reasonably well tolerated, with NR infused faster and with milder side effects than NAD+	The study's own authors state metabolic outcomes were variable and call for larger, longer, placebo-controlled trials before effectiveness can be established

Put plainly: oral precursors have the deepest, most consistent human data, and even that data is limited to biomarkers and functional measures like walking distance, not lifespan or biological age reversal. IV NAD+ has the least rigorous human evidence of the three, despite being the most expensive and the most aggressively marketed as an anti-aging treatment. Cost tends to run in the opposite direction of evidence quality here: oral precursors are the cheapest per month and best-studied, while IV infusions are the priciest per session and least studied.

What hasn't been shown yet

To be specific about the gap: no completed human trial has shown that NMN, NR, or NAD+ IV therapy extends human lifespan. None has shown it reverses an epigenetic clock reading or a validated biological age score in a large, well-controlled study. The 2016 mouse lifespan result that anchors most of the marketing has not been replicated as a lifespan outcome in people, and given how long human lifespan trials take to run, it's unlikely to be for a long time.

Some smaller studies have used biological age calculators as a secondary measure. One 60-day NMN trial found a blood-biomarker-based aging score held steady in the treatment groups while it increased in the placebo group, a genuinely interesting signal. But it's worth being precise about what that calculator was: a clinical biomarker composite score built from standard labs, not a DNA methylation clock and not a validated mortality predictor on its own. Different biological age methods measure different things and don't always agree with each other, which is exactly why a single favorable reading on one calculator, in one small short trial, isn't the same as proof of slowed aging.

None of this means NAD+ supplementation is worthless. It means the honest claim is "reliably raises a biomarker linked to cellular energy and repair, with early positive signals on a few functional measures," not "proven to extend your life." The gap between those two claims is exactly where most of the industry's marketing budget goes.

It's a familiar pattern in supplement science more broadly: a compound with a genuinely interesting animal result and a plausible mechanism gets marketed years, sometimes decades, ahead of the human outcome data that would actually confirm the headline claim. That doesn't make the underlying biology fake. It means the size of the claim on the label should be matched to the size of the evidence behind it, and right now, for NAD+ and longevity specifically, that evidence supports "raises a relevant biomarker" far more confidently than it supports "slows aging" or "extends life."

What a NAD+ protocol can realistically do right now

Given what's actually been measured, here's a fair-minded read on what to expect, separated from what the marketing implies:

• A measurable rise in blood NAD+ levels, if you're using an adequately dosed oral precursor. This is the most consistently replicated finding across trials, and the one you can verify most directly with your own testing.
• Possible improvements in exercise capacity and subjective energy, based on 6-minute walk test and SF-36 wellbeing data in the trials above. These are real, measured endpoints, though sample sizes remain small and results haven't been replicated at scale across diverse populations.
• Possible cardiovascular signals such as reduced arterial stiffness or blood pressure, reported in some oral NR trials in specific populations, that warrant more research before being treated as an established benefit for healthy adults generally.
• No demonstrated change in lifespan or a validated biological age score in any completed human trial to date, regardless of which delivery route or precursor is used.

That's a genuinely useful list for a supplement category. It's also considerably shorter than "boosts longevity" implies, and it's worth going in with that calibration rather than the marketing version. A protocol that reliably moves a relevant biomarker and shows early functional signals is a reasonable thing to try. A protocol marketed as a proven longevity intervention is overselling data that, as of today, doesn't exist yet.

How to know if it's actually working for you

Everything above is population-level trial data. It tells you what happened, on average, in a specific group of 30 to 80 people. It doesn't tell you what's happening in your own blood, because individual response to NAD+ precursors varies substantially. In fact, the same NMN trial that found a dose-dependent average increase in NAD+ also reported wide person-to-person variability in how much any individual's level actually moved, even at the same dose.

That variability is the practical argument for testing rather than assuming. If you're taking NMN, NR, or getting NAD+ IV infusions and want to know whether it's doing anything measurable for you specifically, rather than for the average trial participant, a direct NAD+ panel is the tool built for that question. Boomerang Kits runs the NAD Longevity Blueprint, a CLIA-certified, at-home finger-prick test measuring NAD+, NADH, and total NAD directly, with results back in the Boomerang app in 24 to 48 hours. Test before you start a protocol to get a real baseline, then retest 4 to 8 weeks in, the window in which the trials above saw their biggest biomarker movement, to see whether your number actually moved and by how much. It won't tell you your biological age or your life expectancy. It will tell you, specifically, whether the thing you're paying for is doing the one thing it's actually proven to do.

This also protects you against a quieter problem: product quality. Independent testing of NMN products on the market has repeatedly found that some brands underdeliver on their label claims, meaning a protocol that "should" work on paper may not be working in practice simply because of what's actually in the bottle. A before-and-after NAD+ reading sidesteps that uncertainty entirely, because it measures the outcome that matters, your own blood chemistry, rather than trusting a label.

Frequently asked questions